Antihormone drug resistance

Robert Clarke, V. Craig Jordan

Research output: Chapter in Book/Report/Conference proceedingChapter


The estrogen receptor (ER) has proved to be an excellent target for the treatment and prevention of breast cancer. Although the majority (80%) of breast cancer is ER positive, not all ER positive tumors respond to antihormone therapy. When an ER positive tumor does not respond at all to antihormone therapy it is described to have intrinsic resistance. This contrasts with acquired antihormone resistance where the tumor initially responds with regression but then cell populations expand that grow because of tamoxifen or despite estrogen deprivation. Based on laboratory studies using ER positive cell lines, the evolution of acquired antihormone resistance has been documented. Growth factor pathways expand and subvert the action of the ER at the genome. The new knowledge about molecular mechanisms of resistance has created new opportunities for combinations of antihormone therapies and inhibitors of growth factor pathways.

Original languageEnglish (US)
Title of host publicationEstrogen Action, Selective Estrogen Receptor Modulators, and Women's Health
Subtitle of host publicationProgress and Promise
PublisherImperial College Press
Number of pages29
ISBN (Electronic)9781848169586
ISBN (Print)9781848169579
StatePublished - Jan 1 2013
Externally publishedYes


  • Animal models
  • Aromatase inhibitors
  • Cell cultures
  • Selective estrogen receptor modulators
  • Tamoxifen


Dive into the research topics of 'Antihormone drug resistance'. Together they form a unique fingerprint.

Cite this